ライフサイエンスコーパス: rheumatoid

1 t predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infectio

2 Rheumatoid arthritis (23 [26.7%]), psoriasis (18 [20.9%]

3 .8; 95% confidence interval [CI] = 1.2-2.5), rheumatoid arthritis (adjusted OR = 1.7; 95% CI = 1.5-1.

4 or developing autoimmune diseases, including rheumatoid arthritis (HLA-DRB1*04).

5 hinese, OR = 2.35 in European Americans) and rheumatoid arthritis (OR = 1.65 in Koreans).

6 8.41), or ever having been hospitalized for rheumatoid arthritis (OR = 7.36; 95% CI: 2.95, 18.38).

7 1.27); anemia (OR, 1.19; 95% CI, 1.15-1.25); rheumatoid arthritis (OR, 1.19; 95% CI, 1.10-1.29); coag

8 .58; 95% CI, 1.51-1.66), osteoarthritis with rheumatoid arthritis (OR, 1.58; 95% CI, 1.38-1.82), anti

9 portance of studying individuals at risk for rheumatoid arthritis (pre-RA) and those with early RA (e

10 Rheumatoid arthritis (RA) affects millions world-wide.

11 From 277 patients with rheumatoid arthritis (RA) and 141 healthy individuals, w

12 tory and neurodegenerative diseases, such as rheumatoid arthritis (RA) and AD.

13 in the pathogenesis of systemic inflammatory rheumatoid arthritis (RA) and AD.

14 ible correlation of periodontal disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS

15 Rheumatoid arthritis (RA) and depression may be associat

16 ne dysfunction underlies the pathogenesis of rheumatoid arthritis (RA) and inflammatory bowel disease

17 t prevalent AD is a risk factor for incident rheumatoid arthritis (RA) and inflammatory bowel disease

18 ated TACE-mediated disease models of sepsis, rheumatoid arthritis (RA) and inflammatory bowel disease

19 e development of autoimmune diseases such as rheumatoid arthritis (RA) and is associated with the exp

20 Pain is a dominant symptom of rheumatoid arthritis (RA) and its adequate treatment rep

21 Patients with rheumatoid arthritis (RA) are at higher risk of developi

22 HBV reactivation (HBVr) among patients with rheumatoid arthritis (RA) are incomplete.

23 Current treatments for rheumatoid arthritis (RA) do not reverse underlying aber

24 Rheumatoid arthritis (RA) fibroblast-like synoviocytes (

25 Rheumatoid arthritis (RA) has been associated with endot

26 DNA methylation signatures in rheumatoid arthritis (RA) have been identified in fibrob

27 Genome-wide association studies of rheumatoid arthritis (RA) identified a susceptibility lo

28 d a large-scale MHC fine-mapping analysis of rheumatoid arthritis (RA) in a Japanese population (6,24

29 Pathogenic T cells in individuals with rheumatoid arthritis (RA) infiltrate non-lymphoid tissue

30 KEY POINTS: Rheumatoid arthritis (RA) is a chronic inflammatory cond

31 Rheumatoid arthritis (RA) is a chronic inflammatory cond

32 Rheumatoid arthritis (RA) is a chronic inflammatory cond

33 ABSTRACT: Rheumatoid arthritis (RA) is a chronic inflammatory cond

34 Rheumatoid arthritis (RA) is a heterogeneous, prevalent,

35 Sero-negative rheumatoid arthritis (RA) is a highly heterogeneous diso

36 Rheumatoid Arthritis (RA) is a multisystem disorder, whi

37 Rheumatoid arthritis (RA) is a progressive disease that

38 Rheumatoid arthritis (RA) is a severely debilitating chr

39 Rheumatoid arthritis (RA) is characterized by autoimmune

40 the increased risk of heart failure (HF) in rheumatoid arthritis (RA) is independent of ischemic hea

41 o suggest that autoimmunity in patients with rheumatoid arthritis (RA) is initiated outside the joint

42 The development of rheumatoid arthritis (RA) is linked to functional change

43 The etiology of rheumatoid arthritis (RA) is poorly understood, and 30%

44 revious studies suggest that pathogenesis of rheumatoid arthritis (RA) is similar in all affected joi

45 Rheumatoid arthritis (RA) is the most common inflammator

46 l of recombinant human TRAIL in experimental rheumatoid arthritis (RA) models.

47 rs in healthy donors (HDs) and patients with rheumatoid arthritis (RA) or systemic lupus erythematosu

48 o treat auto-immune related diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosu

49 Rheumatoid arthritis (RA) patients have been observed to

50 uccinate is abundant in synovial fluids from rheumatoid arthritis (RA) patients, and these fluids eli

51 terns by indirect immunofluorescence for 859 rheumatoid arthritis (RA) patients.

52 r disease is a leading cause of morbidity in rheumatoid arthritis (RA) patients.

53 ed from pooled synovial fluid (SF) from four rheumatoid arthritis (RA) patients.

54 status of this pathway in various stages of rheumatoid arthritis (RA) progression is unknown.

55 Recent metabolomics studies of Rheumatoid Arthritis (RA) reported few metabolites that

56 pirical data from a large-scale trans-ethnic rheumatoid arthritis (RA) study and showed that the func

57 When studies on rheumatoid arthritis (RA) that were made many decades ag

58 TNF-alpha is a major cytokine implicated in rheumatoid arthritis (RA), and its expression is regulat

59 er for clinical improvement in patients with rheumatoid arthritis (RA), and macrophages are reduced i

60 arget therapy is effective for patients with rheumatoid arthritis (RA), but long-term results of cont

61 Farming has been associated with rheumatoid arthritis (RA), but the role of pesticides is

62 In rheumatoid arthritis (RA), cartilage and bone matrix are

63 In rheumatoid arthritis (RA), chronic inflammation is thoug

64 code a "shared epitope" (SE) associated with rheumatoid arthritis (RA), especially more severe cyclic

65 Disease activity of rheumatoid arthritis (RA), evaluated as Disease Activity

66 In rheumatoid arthritis (RA), immunological triggers at muc

67 ts, and identified significant enrichment in rheumatoid arthritis (RA), kidney function, and adult he

68 tified over 100 genetic loci associated with rheumatoid arthritis (RA), our ability to translate thes

69 s specific for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), os

70 In patients with rheumatoid arthritis (RA), T cell aging occurs premature

71 In rheumatoid arthritis (RA), the proliferation of fibrobla

72 The mechanisms underlying rheumatoid arthritis (RA)-induced pain are still not ful

73 inhibitors) as agents for the management of rheumatoid arthritis (RA).

74 atologic disease parameters in patients with rheumatoid arthritis (RA).

75 nercept-methotrexate in patients with active rheumatoid arthritis (RA).

76 and T reg cells isolated from patients with rheumatoid arthritis (RA).

77 have a critical role in the pathogenesis of rheumatoid arthritis (RA).

78 etermine the osteoclastogenic role of H4R in rheumatoid arthritis (RA).

79 is a central feature in the pathogenesis of rheumatoid arthritis (RA).

80 major role in invasive joint destruction in rheumatoid arthritis (RA).

81 as investigated for new treatment options in rheumatoid arthritis (RA).

82 hort 46% were female; 71% had a diagnosis of Rheumatoid Arthritis (RA).

83 toimmune diseases: coeliac disease (CeD) and rheumatoid arthritis (RA).

84 tor (RF), are an important characteristic of rheumatoid arthritis (RA).

85 L) is critically involved in bone erosion of rheumatoid arthritis (RA).

86 spectively, in autoimmune diseases including rheumatoid arthritis (RA).

87 is a proinflammatory cytokine implicated in rheumatoid arthritis (RA).

88 se1 in a chronic inflammatory joint disease, rheumatoid arthritis (RA).

89 sclerosis, fibrosis, Alzheimer's disease and rheumatoid arthritis (RA).

90 s has been implicated in the pathogenesis of rheumatoid arthritis (RA).

91 riasis (PsO), psoriatic arthritis (PsA), and rheumatoid arthritis (RA).

92 ) are present in two-thirds of patients with rheumatoid arthritis (RA).

93 eptor mediated inflammatory signaling in the rheumatoid arthritis (RA).

94 and maintenance of autoimmune diseases like rheumatoid arthritis (RA).

95 the chronic inflammatory autoimmune disease rheumatoid arthritis (RA); however, controversial data a

96 cupation of farming has been associated with rheumatoid arthritis (RA); pesticides may account for th

97 control subjects (n = 76) and patients with rheumatoid arthritis (RA, n = 244).

98 x 10(-4)) and for 11 autoimmune diseases and rheumatoid arthritis (RA; P < 1 x 10(-3)).

99 , we identified largest-ever effect on Asian rheumatoid arthritis across human non-HLA regions at GTF

100 gible participants were patients with active rheumatoid arthritis aged at least 18 years, with four o

101 In patients with rheumatoid arthritis and an inadequate response to biolo

102 enrolled patients with active, seropositive rheumatoid arthritis and an inadequate response to synth

103 in the inflamed synovium from patients with rheumatoid arthritis and compared with synovium from hea

104 ssociated with inflammatory diseases such as rheumatoid arthritis and Crohn's disease.

105 inical investigations and clinical trials in rheumatoid arthritis and follicular lymphoma.

106 lammatory reflex to significantly ameliorate rheumatoid arthritis and inflammatory bowel disease prov

107 eases such as cancer, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease), me

108 of-concept is established for immune-related rheumatoid arthritis and inflammatory bowel disease, as

109 various inflammatory disease models, such as rheumatoid arthritis and inflammatory bowel disease.

110 ity, and deregulated PGRN is associated with rheumatoid arthritis and inflammatory bowel disease.

111 e IL-6 pathway, has been approved for use in rheumatoid arthritis and interest in transplantation has

112 improve other autoimmune diseases, including rheumatoid arthritis and multiple sclerosis.

113 bitor treatment in patients seropositive for rheumatoid arthritis and naive to treatment with biologi

114 y, is under development for the treatment of rheumatoid arthritis and other diseases.

115 eting IL-20 is effective in the treatment of rheumatoid arthritis and psoriasis, both with strong GWA

116 he genetic overlap observed between PTSD and rheumatoid arthritis and psoriasis.

117 nically approved agents for the treatment of rheumatoid arthritis and renal transplantation, respecti

118 Apoptotic CD4(+) T cells from patients with rheumatoid arthritis and systemic lupus erythematosus we

119 viously been implicated in severity of human rheumatoid arthritis and systemic lupus erythematosus, i

120 nd, more common autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, s

121 ts who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascula

122 of pleiotropy was observed between PTSD and rheumatoid arthritis and, to a lesser extent, psoriasis.

123 nective tissue diseases (CTD) like lupus and rheumatoid arthritis associate with cardiovascular risk,

124 e aged 18 years or older with a diagnosis of rheumatoid arthritis at screening, as defined by the 201

125 control of inflammation optimise outcomes in rheumatoid arthritis but these approaches have not yet b

126 s) and European (n = 45,790; 11 collections) rheumatoid arthritis case-control cohorts with Immunochi

127 core in 28 joints (DAS28) was calculated and rheumatoid arthritis classification criteria applied.

128 D-naive, aged 18 years or older, met current rheumatoid arthritis classification criteria, and had a

129 The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) tri

130 shock protein 90 (HSP90) are associated with rheumatoid arthritis complicated by interstitial lung di

131 pes were constructed for 213 AS cases and 46 rheumatoid arthritis controls using family data.

132 nt genetic studies in the KRN mouse model of rheumatoid arthritis demonstrate that the immunomodulato

133 ding TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are la

134 patients aged 18 years or older with active rheumatoid arthritis despite methotrexate therapy.

135 medication (OR = 3.98; 95% CI: 2.08, 7.62), rheumatoid arthritis duration of 6-20 years (OR = 3.80;

136 channel expressed at the plasma membrane of rheumatoid arthritis fibroblast-like synoviocytes (RA-FL

137 beta1-integrin function and cell adhesion in rheumatoid arthritis fibroblast-like synoviocytes.

138 es of treatment response in the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndica

139 applying it to Genetic Analysis Workshop 16 rheumatoid arthritis GWAS data.

140 Studies in patients with rheumatoid arthritis have shown that the rituximab biosi

141 ess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T).

142 Rheumatoid arthritis in Agricultural Health Study spouse

143 drug or gene delivery and novel therapy for rheumatoid arthritis in an in situ forming gel formulati

144 with distinct effects on the development of rheumatoid arthritis in Asian and European populations.

145 mumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequ

146 xate combination therapy in the treatment of rheumatoid arthritis in patients with an inadequate resp

147 Patients with rheumatoid arthritis in remission exhibited high numbers

148 Rheumatoid arthritis is a chronic autoimmune disease tha

149 Rheumatoid arthritis is a chronic autoimmune disorder re

150 Rheumatoid arthritis is a chronic disease that results i

151 Rheumatoid arthritis is a chronic inflammatory disease c

152 Rheumatoid arthritis is a chronic inflammatory joint dis

153 Rheumatoid arthritis is a complex disease associated wit

154 Rheumatoid arthritis is an autoimmune disease resulting

155 Rheumatoid arthritis is an autoimmune disease that is ch

156 Rheumatoid arthritis is an autoimmune disorder character

157 Rheumatoid arthritis is an autoimmune disorder that affe

158 Rheumatoid arthritis is an inflammatory condition charac

159 Rheumatoid arthritis is characterised by synovial inflam

160 c role at sites of autoimmunity, such as the rheumatoid arthritis joint where they accumulate.

161 or tofacitinib's success in the treatment of rheumatoid arthritis led to biopharma's abandonment of i

162 rthritis, such as ever having received daily rheumatoid arthritis medication (OR = 3.98; 95% CI: 2.08

163 ry complications contribute significantly to rheumatoid arthritis mortality.

164 nd observational studies involved those with rheumatoid arthritis or inflammatory bowel disease.

165 TonEBP signaling in inflammatory disease and rheumatoid arthritis pathogenesis.

166 RvD3 was also reduced in serum from rheumatoid arthritis patients compared with healthy cont

167 e formation, while DCs from CTLA4-Ig-treated rheumatoid arthritis patients displayed diminished LC3B

168 torial staining approach to demonstrate that rheumatoid arthritis patients on therapy can mount effec

169 of platelets with synovial fluid cells from rheumatoid arthritis patients reduced inflammatory cytok

170 diovascular events in psoriasis patients and rheumatoid arthritis patients treated with tumor necrosi

171 ces to inhibit cytokines and inflammation in rheumatoid arthritis patients, and provided a mosaic vie

172 t ex-Th17 cells accumulated in the joints of rheumatoid arthritis patients.

173 pressed IL-17A production in human PBMC from rheumatoid arthritis patients.

174 nclusions and Relevance: Among patients with rheumatoid arthritis previously treated with anti-TNF dr

175 ediates the beneficial actions of statins in rheumatoid arthritis remains of interest.

176 role of endogenous glucocorticoids (GCs) in rheumatoid arthritis remains unclear.

177 Importance: One-third of patients with rheumatoid arthritis show inadequate response to tumor n

178 In the Wellcome Trust Rheumatoid Arthritis study, STAMS-identified modules wer

179 subset of late phase genes was expressed in rheumatoid arthritis synovial macrophages, confirming th

180 Antagonizing IL-1beta with Anakinra, a rheumatoid arthritis therapeutic, prevented detrusor pro

181 ritical for the induction and progression of rheumatoid arthritis through its pivotal role in the dev

182 Up to 40% of patients with rheumatoid arthritis treated with anti-tumour necrosis f

183 The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to asse

184 r, reduced disease activity in patients with rheumatoid arthritis who had not previously received tre

185 A 54-year-old white woman with a history of rheumatoid arthritis who was taking glucocorticoids and

186 INTERPRETATION: In patients with active rheumatoid arthritis who were refractory or intolerant t

187 risk of serious infections in patients with rheumatoid arthritis who were treated with biological dr

188 ncluded patients who had been diagnosed with rheumatoid arthritis within 1 year before inclusion, wer

189 o systemic (systemic lupus erythematosus and rheumatoid arthritis) and two organ-specific (multiple s

190 2 diabetes mellitus, multiple sclerosis, or rheumatoid arthritis) were included for comparison.

191 characterized in autoimmune disorders (e.g., rheumatoid arthritis), but there are some exceptional lo

192 ectal carcinoma), and an autoimmune disease (rheumatoid arthritis).

193 sorders (e.g., systemic lupus erythematosus, rheumatoid arthritis).

194 ultiple sclerosis, sarcoidosis, and juvenile rheumatoid arthritis).

195 Inclusion criteria were (i) patients with rheumatoid arthritis, (ii) adult population age >/=16yea

196 ; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammator

197 We included 16 studies (9 of patients with rheumatoid arthritis, 8 of patients with inflammatory bo

198 d T cells in joint tissue from patients with rheumatoid arthritis, a chronic immune-mediated arthriti

199 en periodontitis and cardiovascular disease, rheumatoid arthritis, Alzheimer's disease, pulmonary dis

200 re profoundly protected in several models of rheumatoid arthritis, and Ab blockade of G-CSF also prot

201 onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer.

202 act of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastating monogenic disorder

203 infections, allergies, autoimmune diseases, rheumatoid arthritis, and inflammatory bowel disease.

204 this system has been noted in patients with rheumatoid arthritis, and its pathogenic role has been c

205 teers, phase 3 trials involved patients with rheumatoid arthritis, and observational studies involved

206 tension, cognitive function, kidney disease, rheumatoid arthritis, and quality of life.

207 plied our method to data on gene expression, rheumatoid arthritis, and type 2 diabetes and overwhelmi

208 in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.

209 therapies, however, which are effective for rheumatoid arthritis, are either ineffective for psorias

210 This disease network portraits rheumatoid arthritis, asthma, atherosclerosis, pulmonary

211 n are highly effective treatments for active rheumatoid arthritis, but so far no randomised controlle

212 ion covering gene DSC3 being associated with rheumatoid arthritis, but the GCP provides smaller P-val

213 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis, and mul

214 es the severity of various illnesses such as rheumatoid arthritis, diabetes, and liver diseases.

215 ons (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalgia) than those with NWU

216 uids may lead to different diseases, such as rheumatoid arthritis, glomerulonephritis, etc.

217 ed cytokines in autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease, and sy

218 emonstrated to provide a therapeutic role in rheumatoid arthritis, inflammatory intestinal disease, c

219 to chronic autoimmune inflammation, such as rheumatoid arthritis, is ill defined and probably requir

220 ddison's disease, primary biliary cirrhosis, rheumatoid arthritis, juvenile idiopathic arthritis, and

221 ed CRP levels with psoriatic osteoarthritis, rheumatoid arthritis, knee osteoarthritis, systolic bloo

222 ring the complex role of IL-33 in a model of rheumatoid arthritis, namely, collagen-induced arthritis

223 enous IL-1 receptor antagonist used to treat rheumatoid arthritis, normalizes hippocampal neurotransm

224 wn to be effective in managing patients with rheumatoid arthritis, patient outcomes sensitive to nurs

225 chronic conditions such as atherosclerosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

226 cancers and increased risks for lung cancer, rheumatoid arthritis, Sjogren syndrome, and Raynaud synd

227 he development of autoimmunity, particularly rheumatoid arthritis, still needs extensive exploration.

228 For patients with newly diagnosed rheumatoid arthritis, strategies aimed at sustained remi

229 sk was higher when we used proxies of severe rheumatoid arthritis, such as ever having received daily

230 sue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutr

231 For patients with newly diagnosed rheumatoid arthritis, treatment aim is early, rapid, and

232 ge 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, celiac disease, a

233 jacent to GAK, HLA-DRB5, LRRK2, and MAPT for rheumatoid arthritis, ulcerative colitis and Crohn disea

234 patients (conducted between 2009-2012) with rheumatoid arthritis, with persistent disease activity (

235 Comparison groups included patients with rheumatoid arthritis-associated ILD (RA-ILD; n = 33), pa

236 l-length sgp130 and the shorter forms sgp130-rheumatoid arthritis-associated peptide (RAPS) and sgp13

237 uals, and occasionally leads to seronegative rheumatoid arthritis-like pathologies.

238 Lung complications are a major cause of rheumatoid arthritis-related mortality.

239 ases, including cancer, atherosclerosis, and rheumatoid arthritis.

240 D1 expression with decreased bone erosion in rheumatoid arthritis.

241 synoviocytes contributes to joint damage in rheumatoid arthritis.

242 eukin-6 (IL-6) in inflammatory diseases like rheumatoid arthritis.

243 type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis.

244 ular disease and exert beneficial actions in rheumatoid arthritis.

245 diabetes, systemic lupus erythematosus, and rheumatoid arthritis.

246 , allergic asthma, autoimmune nephritis, and rheumatoid arthritis.

247 Janus kinase inhibitor for the treatment of rheumatoid arthritis.

248 )CD4(+) T cells in synovium of patients with rheumatoid arthritis.

249 mmatory networks that subserve diseases like rheumatoid arthritis.

250 potential therapeutic target for suppressing rheumatoid arthritis.

251 damage in murine models of inflammatory and rheumatoid arthritis.

252 ty of chronic inflammatory diseases, such as rheumatoid arthritis.

253 mune diseases, including type 1 diabetes and rheumatoid arthritis.

254 ent of autoimmune diseases such as lupus and rheumatoid arthritis.

255 s together with unmet needs of patients with rheumatoid arthritis.

256 thological conditions, such as pregnancy and rheumatoid arthritis.

257 in biological-treatment naive patients with rheumatoid arthritis.

258 file and is efficacious in a rodent model of rheumatoid arthritis.

259 nse, leukaemia, age-related hearing loss and rheumatoid arthritis.

260 rophage-driven inflammatory diseases such as rheumatoid arthritis.

261 se, autoimmune thyroid disease, and juvenile rheumatoid arthritis.

262 T cell dysregulation as a central problem in rheumatoid arthritis.

263 usceptibility to autoimmune disease, notably rheumatoid arthritis.

264 syndromes, such as cardiovascular disease or rheumatoid arthritis.

265 plex (MHC) across all three study cohorts of rheumatoid arthritis.

266 of these IgGs can be used as biomarkers for rheumatoid arthritis.

267 rrelated in joint synovia from patients with rheumatoid arthritis.

268 is associated with the inflammatory state of rheumatoid arthritis.

269 t target these molecules in diseases such as rheumatoid arthritis.

270 ies including hematological malignancies and rheumatoid arthritis.

271 nd the life expectancy of many patients with rheumatoid arthritis.

272 rders such as inflammatory bowel disease and rheumatoid arthritis.

273 or (uPAR) in joint tissue from patients with rheumatoid arthritis.

274 raits, such as the interleukin-27 pathway in rheumatoid arthritis.

275 esis of BI 653048, a compound active against rheumatoid arthritis.

276 orted nursing interventions in patients with rheumatoid arthritis.

277 factor alpha blocker currently used to treat rheumatoid arthritis.

278 lammatory bowel disease, Crohn's disease and rheumatoid arthritis.

279 eported after IL-6 blockade in patients with rheumatoid arthritis.

280 nt or clinical use for indications including rheumatoid arthritis.

281 , including systemic lupus erythematosus and rheumatoid arthritis.

282 ent types of CTD were analyzed individually (rheumatoid arthritis; lupus; scleroderma; Sjogren Syndro

283 were suppressed in macrophages isolated from rheumatoid-arthritis patients, revealing a disease-assoc

284 ortant insights on RA and on the function of rheumatoid factor (RF) become apparent.

285 Urinalysis and rheumatoid factor (RF) tests were conducted to evaluate

286 Autoantibodies, including rheumatoid factor (RF), are an important characteristic

287 an biomarkers for the classification of both rheumatoid factor (RF)-positive and negative RA patients

288 profile, level of alanine aminotransferase, rheumatoid factor activity, C4 fraction of complement, a

289 t circulating autoantibodies, including both rheumatoid factor and anti-citrullinated protein antibod

290 Blood chemistry tests revealed a rheumatoid factor of 8.5 IU/mL (normal range, 0-13.9 IU/

291 adjustment for CVD risk factors, joint pain, rheumatoid factor positivity, and inflammatory markers (

292 n non-B cells, we transferred anti-self-IgG (rheumatoid factor) B cells and their physiologic target

293 otein, erythrocyte sedimentation rate (ESR), rheumatoid factor, anticitrullinated protein antibodies

294 re disease progression, including a positive rheumatoid factor, or anti-cyclic citrullinated peptide

295 In 358 children with oligoarthritis and rheumatoid factor-negative polyarthritis, erythrocyte se

296 pendent autoreactive EF response elicited in rheumatoid-factor B cells by DNA-containing immune compl

297 Sjogren's syndrome, porphyria cutanea tarda, rheumatoid-like arthritis, or depression.

298 tance of periodontal pathogenic bacteria and rheumatoid parameters in the interrelationship between p

299 NKL expression in both primary RA SF and the rheumatoid synovial fibroblast cell line, MH7A.

300 anscription analysis of ICBP90 shRNA-treated rheumatoid synoviocytes uncovered a subset of proinflamm